Agios Pharmaceuticals (AGIO) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseZacks Investment Research • 10/22/20
Agios to Webcast Conference Call of Third Quarter 2020 Financial Results on November 5, 2020GlobeNewsWire • 10/22/20
Agios Announces Withdrawal of European Marketing Authorization Application for TIBSOVO® as a Treatment for Relapsed or Refractory IDH1-mutant Acute Myeloid LeukemiaGlobeNewsWire • 10/16/20
All You Need to Know About Agios Pharmaceuticals (AGIO) Rating Upgrade to BuyZacks Investment Research • 10/05/20
Agios Announces Final Overall Survival Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Previously Treated IDH1-Mutant Cholangiocarcinoma PatientsGlobeNewsWire • 09/21/20
Agios Appoints Jonathan Biller as Chief Financial Officer, Head of Legal and Corporate AffairsGlobeNewsWire • 09/08/20
Agios Pharmaceuticals (AGIO) Down 15.5% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 08/29/20
Agios to Present at the Citi 15th Annual BioPharma Virtual Conference on Wednesday, September 9, 2020GlobeNewsWire • 08/27/20
Agios to Present at the Virtual Canaccord 40th Annual Growth Conference on Thursday, August 13, 2020GlobeNewsWire • 08/06/20
Agios Pharmaceuticals, Inc. (AGIO) CEO Jacqualyn Fouse on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 07/30/20
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 07/23/20
Agios to Webcast Conference Call of Second Quarter 2020 Financial Results on July 30, 2020GlobeNewsWire • 07/16/20
Agios Pharmaceuticals (AGIO) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 06/18/20
Agios to Present at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference on Tuesday, June 23, 2020GlobeNewsWire • 06/17/20
Agios and Royalty Pharma Announce $255 Million Purchase Agreement for IDHIFA® RoyaltyGlobeNewsWire • 06/12/20
Agios Announces Clinical Proof-of-Concept Has Been Established in Phase 1 Study of Mitapivat, First-in Class PKR Activator, in Sickle Cell DiseaseGlobeNewsWire • 06/12/20
Agios First-in Class PKR Activator Mitapivat Demonstrates Sustained Hemoglobin Responses in Non-transfusion-dependent α- and β-Thalassemia in Phase 2 StudyGlobeNewsWire • 06/12/20
Has Agios Pharmaceuticals (AGIO) Outpaced Other Medical Stocks This Year?Zacks Investment Research • 06/10/20
Agios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of ThalassemiaGlobeNewsWire • 06/08/20